News
GlyTherix is a recipient of the first round of the TIA pipeline accelerator 2020-21 scheme
GlyTherix Ltd is proud to be a recipient of the first round of the Pipeline Accelerator 2020-21 scheme from Therapeutic Innovation Australia (TIA). Round 1 saw the award of $685,000 to 21 projects. Our project “Optimisation and characterisation of Miltuximab®-DFO...
Carina Biotech and GlyTherix enter into CAR-T partnership
PRESS RELEASE September 10, 2020 Adelaide, Australia and Sydney, Australia. CAR-T biotherapeutics company Carina Biotech and immuno-oncology company GlyTherix are pleased to announce a co-development agreement that could result in a promising new CAR-T therapy that is...
Glytherix seeks AUD 7M Series A funding after securing grant – CEO
Recently GlyTherix’s CEO Brad Walsh shared an update on the company with Louise Weihart from Acuris Mergermarket. Briefly, it was said that GlyTherix Ltd is seeking AUD 7M in a Series A equity round, after securing up to AUD 3M in non-dilutive funding from Round 9 of...
GlyTherix Awarded $3 Million Co-operative Research Centre Project Grant
16th July 2020: Sydney • Project boasts a dream team of world class partners across antibody manufacturing and clinical trials • Grant will support development of national capability in manufacture and distribution of radioimmuno-oncology drugs • GlyTherix’s...
Industry News: MTPConnect’s COVID-19 Impact Report
Explore the impact of the pandemic lockdown on medtech, biotech and pharma sectors in Australia by downloading MTPConnect’s COVID-19 Impact Report.
Four New Peer Reviewed Papers Underline the Strength of the GlyTherix Technology
Tuesday 19th May 2020: Sydney GlyTherix Ltd (GlyTherix) is pleased to report publication of four new peer reviewed papers covering both basic science as well as pre-clinical studies around our proprietary novel target, Glypican-1 and our lead antibody to this target,...
GlyTherix is presenting at AusBiotech Invest & Partnering 2019
GlyTherix is among 25 biotech companies presenting at the AusBiotech Invest & Partnering Session on Thursday 31 October at Melbourne Convention & Exhibition Centre. Brad Walsh will provide an update on Miltuximab, the company’s novel treatment for solid...
GlyTherix Ltd is presenting at AusBiotech Asian Investment Series
GlyTherix Ltd is one of 25 Australian life science companies presenting new business opportunities to international investors during the Asian investment series, hosted by AusBiotech. The events are on 26 March in Hong Kong and 28-29 March in Shanghai and will attract...
Minomic announces completion of demerger of GlyTherix Ltd
Demerger clears the path for therapeutic company capital raising Sydney, Australia, 25 September 2018: Minomic International Ltd is pleased to announce it received strong shareholder approval to approve the demerger of its therapeutic subsidiary, GlyTherix Ltd,...
Minomic announces completion of accrual for clinical study of Miltuximab® in prostate, bladder and pancreatic cancers
No drug-related adverse effects found in patients Sydney, Australia, 24th July 2018: Minomic International Ltd (Minomic) is an immuno-oncology company specializing in therapeutics and diagnostics for solid tumors, including prostate, bladder and pancreas. The Company...
ASCO meeting abstract: Glypican-1 as a novel immunotherapeutic target in prostate cancer
A poster on Glypican-1 as a novel immunotherapeutic target in genitourinary cancers was presented by Dr Douglas Campbell, Minomic's head of R&D at the 2018 ASCO Genitourinary Cancers Symposium in San Francisco. Preliminary in vitro ADCC assay results revealed the...